Market Overview

Impax Labs Enters Commercialization Deal with Perrigo

Related PRGO
Analyst: Mylan Shareholders Might Get Convinced By Vigodman Letter
Benzinga's M&A Chatter for Wednesday April 29, 2015
M&A Fever Grips Drugmakers (Investor's Business Daily)
Related IPXL
UBS Says Impax 'Ahead Of Itself,' Downgrades To Sell
Benzinga's Top Downgrades
What is in Store for Aegerion (AEGR) This Earnings Season? - Analyst Blog (Zacks)

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company (NASDAQ: PRGO;TASE) on the development, manufacturing and commercialization of an extended topical generic drug product with first to market potential. The product and terms of the agreement were not disclosed.

Posted-In: News


Related Articles (IPXL + PRGO)

Around the Web, We're Loving...